EUSTAR网络RESIST评分:预测早期死亡以分层强化治疗
基于EUSTAR队列开发RESIST评分,用于预测适合强化治疗的SSc患者5年内死亡风险。纳入4526例患者,138例5年内死亡,评分将患者分为低、中、高危三组,5年生存率分别为99%、96%和82%,开发与验证队列AUC分别为0.79和0.78。
要点
- RESIST评分纳入男性、dcSSc、年龄>55岁、CRP升高、指端溃疡等8项指标
- 评分可将患者分为低危(5年生存率99%)、中危(96%)、高危(82%)三组
- 开发队列AUC 0.79,伪外部验证队列AUC 0.78,区分度良好
核心结论
- RESIST评分可可靠预测适合强化治疗的SSc患者早期死亡风险,有助于识别高死亡风险患者并指导治疗决策。
研究设计与样本
- 基于EUSTAR队列,排除不适合强化治疗的患者,采用Kaplan-Meier法分析生存,构建含自适应LASSO选择的多变量Cox模型。
- 共纳入4526例患者,其中138例5年内死亡;在6251例被排除患者中进行伪外部验证。
主要发现
- 死亡患者较存活者更多为男性(28% vs 16%)、年龄更大(53 vs 49岁)、弥漫性皮肤型SSc比例更高(61% vs 35%)。
- RESIST评分纳入男性、dcSSc、年龄>55岁、CRP升高、指端溃疡、mRSS>14、LVEF<60%、DLCO<60%。
- 低危、中危、高危组5年生存率分别为99%(95%CI 98%-100%)、96%(95%CI 95%-97%)、82%(95%CI 78%-87%)。
- 开发队列AUC为0.79(0.77-0.79),验证队列AUC为0.78(0.77-0.79)。
临床怎么用
- 对于考虑强化治疗的SSc患者,可用RESIST评分评估早期死亡风险,高危患者需谨慎权衡治疗获益与风险。
局限性
- 验证为伪外部验证,非独立外部队列验证;原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Systemic sclerosis (SSc) is associated with increased mortality. Intensive therapies have emerged for severe or refractory cases, but carry significant risks. The Risk score for Early mortality to Stratify for Intensive SSc Therapy (RESIST) score was developed to predict early mortality (<5 years) in patients eligible for such treatments. METHODS: Using the European League Against Rheumatism Scleroderma Trials and Research (EUSTAR) cohort, patients unsuitable for intensive therapy were excluded. Survival was analysed via Kaplan-Meier estimates. A multivariable Cox model with adaptive LASSO (Least Absolute Shrinkage and Selection Operator) selection was built, informed by expert opinion, univariable analyses, and literature. Model performance was evaluated using the concordance index, area under the curve (AUC) at 3 and 5 years, and calibration. Missing data were imputed, and pseudo external validation was performed on 6251 excluded patients. RESULTS: Of 22,059 EUSTAR patients, 4526 met the inclusion criteria; 138 died within 5 years. Deceased patients were more often male (28% vs 16%), older (53 vs 49 years), and had diffuse cutaneous SSc (dcSSc) (61% vs 35%) compared to survivors. The RESIST score included: male sex; dcSSc; age >55 years; elevated C-reactive protein; digital ulcers; modified Rodnan skin score >14; left ventricular ejection fraction <60%; and diffusing capacity of the lung for carbon monoxide <60%. This allowed patients with SSc to be discriminated into 3 groups with the following 5-year survival rates: low risk (99%, 95% CI: 98%-100%), intermediate risk (96%, 95% CI: 95%-97%), and high risk (82%, 95% CI: 78%-87%). The model showed good discrimination in both the development and validation cohorts (AUC: 0.79 [0.77-0.79] and 0.78 [0.77-0.79], respectively). CONCLUSIONS: The RESIST score reliably predicts early mortality in patients with SSc eligible for intensive therapies and may guide treatment decisions by identifying those at high risk of death.
引用
- Pecher AC, Boubaya M, Allanore Y, et al. Risk score for early mortality to stratify for intensive SSc therapy in the EUSTAR network: the RESIST score. Ann Rheum Dis. 2026. PMID: 41846198. doi:10.1016/j.ard.2026.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。